# China NMPA Drug Inspection - Beijing Tongrentang (Bozhou) Pharmaceutical Co., Ltd. - Albizia

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/beijing-tongrentang-bozhou-pharmaceutical-co-ltd/b25268f8-c79e-45dd-84c6-cb1f978db8bf/
Source feed: China

> China NMPA drug inspection for Beijing Tongrentang (Bozhou) Pharmaceutical Co., Ltd. published July 07, 2017. Drug: Albizia. The Tianjin Municipal Market and Quality Supervision and Management Commission issued a Drug Quality Announcement on Jul

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Tianjin Municipal Drug Quality Bulletin (2017, Issue 2, Serial No. 29)
- Company Name: Beijing Tongrentang (Bozhou) Pharmaceutical Co., Ltd.
- Publication Date: 2017-07-07
- Drug Name: Albizia
- Inspection Finding: Non-compliant items: [Inspection] Total ash, acid-insoluble ash, [Leachate]
- Action Taken: The municipal market supervision and law enforcement departments at all levels have promptly investigated and dealt with the aforementioned substandard drugs discovered during the supervision and sampling inspection in accordance with the law.
- Summary: The Tianjin Municipal Market and Quality Supervision and Management Commission issued a Drug Quality Announcement on July 7, 2017, detailing findings from its 2017 drug supervision and sampling inspection program. These inspections, conducted across drug production, operation, and use stages in Tianjin, aimed to strengthen drug oversight and ensure public safety. Three batches of drugs were identified as substandard, failing to meet the quality standards prescribed by the Chinese Pharmacopoeia. Hebei Chunkai Pharmaceutical Co., Ltd.'s 'Winter Melon Peel' (batch 150801135) was found substandard in appearance. Anguo Shenhao Pharmaceutical Co., Ltd.'s 'Earthworm (Dilong)' (batch 161001) failed inspections for Total Ash and Acid-Insoluble Ash. Lastly, 'Albizia Flower (Hehuanhua)' (batch 600002600), attributed to Beijing Tongrentang (Bozhou) Pharmaceutical Pieces Co., Ltd., was deemed unqualified due to deviations in Total Ash, Acid-Insoluble Ash, and Extractives. Notably, remarks accompanying the first and third findings indicated that the named manufacturers denied producing the specific substandard batches, suggesting potential issues in the drug supply chain or misidentification. In response to these findings, municipal market supervision and law enforcement departments were mandated to promptly investigate and address the substandard drugs in accordance with relevant laws, safeguarding local drug quality and public health. This announcement underscores ongoing regulatory efforts to maintain high drug safety standards.

Company: https://www.globalkeysolutions.net/companies/beijing-tongrentang-bozhou-pharmaceutical-co-ltd/7216e765-9728-4313-a8dd-7ea1d6ac6377/